This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Peak Investment Capital
Ruback, Richard S.; Yudkoff, RoyceCase HBS-219061-EEntrepreneurshipKobbina Awuah (MBA 2014) became intrigued with the possibility of adapting Entrepreneurship through Acquisition in Ghana, where he grew up and where his family still lived. While he knew he could work for a multi-national enterprise located in Ghana, he was confident that buying a small business to run provided an opportunity to have more of an impact. He formed Peak Investment Capital (PIC) at the beginning of 2014 with the goal of finding a bus...Starting at €8.20
-
Business Succession and the Asher Estate - Teaching Note
Stephen Sapp; Alykhan AlidinaTeaching Note IVEY-8B20N011-EFinanceTeaching note for product 9B20N011.Starting at €0.00
-
Magna International and Dual Share Unification - Teaching Note
W. Glenn Rowe; Stephen Sapp; Nadine de Gannes; Abbas KhambatiTeaching Note IVEY-8B20M209-EStrategyTeaching note for product 9B20M209.Starting at €0.00
-
KTM - Venture Capitalist Exit
Stephen Sapp; Charlene Zietsma; Iris Fischlmayr; Rob WongCase IVEY-9B07N003-EEntrepreneurship, Finance, StrategyKTM is a small motorcycle manufacturing company located in Austria. As a result of difficult economic conditions in 1999, KTM went private with the help of the venture capital firm BC European Capital (BC). Following a couple of years of strong growth, BC is looking to liquidate its position and move on. KTM is faced with the decision of determining the best means to repurchase BC's equity position in the firm and leave the firm with enough finan...Starting at €8.20
-
CanniMed Therapeutics: Acquiror or Target
Stephen Sapp; Shane FreedmanCase IVEY-9B20N008-EEntrepreneurship, FinanceOn November 14, 2017, Aurora Cannabis Inc. (Aurora) made a proposal to CanniMed Therapeutics Inc. (CanniMed) to acquire all of CanniMed’s issued and outstanding common shares in a share exchange that valued CanniMed’s common shares at a premium of almostStarting at €8.20
-
CS Publishing Inc.: Foreign Exchange Risk Management - Teaching Note
Stephen SappTeaching Note IVEY-8B19N024-EFinanceTeaching note for product 9B19N024.Starting at €0.00
-
CanniMed Therapeutics: Acquiror or Target - Teaching Note
Stephen SappTeaching Note IVEY-8B20N008-EFinanceTeaching note for product 9B20N008.Starting at €0.00
-
East Cameron Partners: The Sukuk Bond
Stephen Sapp; Brooke HarleyCase IVEY-9B10N014-EEntrepreneurship, Finance, StrategyThe chief executive officer (CEO) of East Cameron Partners LP, is interested in raising capital to buy out his existing 50 per cent partner thereby regaining control of the firm and enabling him to finance new growth. Because of the risky nature of the oil and gas business and relatively small size of East Cameron, the CEO has limited alternatives available to him. The case discusses the standard alternatives available to small and medium sized e...Starting at €8.20
-
Hydro One Inc.: CEO Compensation
Stephen Sapp; Ramasastry ChandrasekharCase IVEY-9B10N002-EAccounting and Control, Finance, Leadership and People Management, StrategyThe case presents the situation faced by the board of directors at Hydro One, a government-owned Canadian electric utility, as they discuss updating the current executive compensation packages because of the pending privatization of Hydro One. As a government owned enterprise, compensation was moderated by the job security and prospects of career advancement in the public sector, but the imminent privatization required the compensation system to ...Starting at €8.20
-
JP Morgan: Lessons Learned
Stephen SappCase IVEY-9B12N024-EFinanceFollowing the revelation of a US$2 billion loss on trading at JP Morgan’s chief investment office (CIO) in London, the company’s board of directors is tasked with recommending changes to its risk management practices and corporate governance structure. The case provides background on JP Morgan's well-respected risk management infrastructure and discusses how the CEO focused on its historic strength in risk management to argue against the need for...Starting at €8.20